Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Cairo Mitchell S.) > Outcomes of rituxim...

Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

Jagadeesh, Deepa (författare): Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.

Majhail, Navneet S. (författare): Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA.

He, Yizeng (författare): Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA.

visa fler...

Ahn, Kwang W. (författare): Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

Litovich, Carlos (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

Ahmed, Sairah (författare): Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.

Aljurf, Mahmoud (författare): King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.

Bacher, Ulrike (författare): Univ Bern, Bern Univ Hosp, Inselspital, Dept Hematol, Bern, Switzerland.

Badawy, Sherif M. (författare): Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL 60611 USA.;Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA.

Bejanyan, Nelli (författare): H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.

Cairo, Mitchell (författare): New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA.;Ohio State Univ, Dept Med, James Canc Hosp, Div Hematol, Columbus, OH 43210 USA.

Cerny, Jan (författare): Univ Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA.

Epperla, Narendranath (författare): Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.

Farhadfar, Nosha (författare): Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA.

Freytes, Cesar O. (författare): Texas Transplant Inst, San Antonio, TX USA.

Gale, Robert Peter (författare): Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England.

Haverkos, Bradley (författare): Univ Colorado Hosp, Aurora, CO USA.

Hossain, Nasheed (författare): Loyola Univ, Chicago Stritch Sch Med, Dept Med, Stem Cell Transplant Program,Div Hematol Oncol, Maywood, IL 60153 USA.

Inwards, David (författare): Mayo Clin, Div Hematol, Rochester, MN USA.

Kamble, Rammurti T. (författare): Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.

Kenkre, Vaishalee P. (författare): Univ Wisconsin, Div Hematol Oncol, Madison, WI USA.

Lazarus, Hillard M. (författare): Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA.

Lazaryan, Aleksandr (författare): H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.

Lekakis, Lazaros (författare): Univ Miami, Dept Hematol Oncol, Miami, FL USA.

Mei, Matthew (författare): City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA.

Murthy, Hemant S. (författare): Mayo Clin Florida, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA.

Mussetti, Alberto (författare): Inst Catala Oncol Hosp, Dept Hematol, Barcelona, Spain.;IDIBELL Inst Catala Oncol, Lhospitalet De Llobregat, El Prat De Llob, Spain.

Nathan, Sunita (författare): Rush Univ, Div Hematol Oncol & Cell Therapy, Med Ctr, Chicago, IL 60612 USA.

Nishihori, Taiga (författare): H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.

Olsson, Richard (författare): Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.

Geethakumari, Praveen Ramakrishnan (författare): Univ Texas Southwestern Med Ctr, Lymphoma BMT & Cellular Therapy Program, Dallas, TX USA.

Savani, Bipin N. (författare): Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.

Yared, Jean A. (författare): Univ Maryland, Dept Med, Blood & Marrow Transplantat Program, Greenebaum Comprehens Canc Ctr,Div Hematol Oncol, Baltimore, MD 21201 USA.

Fenske, Timothy S. (författare): Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA.

Kharfan-Dabaja, Mohamed A. (författare): Mayo Clin Florida, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA.

Sureda, Anna (författare): Inst Catala Oncol Hosp, Dept Hematol, Barcelona, Spain.;IDIBELL Inst Catala Oncol, Lhospitalet De Llobregat, El Prat De Llob, Spain.

Hamadani, Mehdi (författare): Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.

visa färre...

Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. (creator_code:org_t)

2020-02-12
2020
Engelska.
Ingår i: Cancer. - : WILEY. - 0008-543X .- 1097-0142. ; 126:10, s. 2279-2287

Relaterad länk:: https://acsjournals....; visa fler...; https://urn.kb.se/re...; https://doi.org/10.1...; http://kipublication...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

BACKGROUND Although rituximab-based high-dose therapy is frequently used in diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT), data supporting the benefits are not available. Herein, we report the impact of rituximab-based conditioning on auto-HCT outcomes in patients who have DLBCL. METHODS Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, 862 adult DLBCL patients undergoing auto-HCT between 2003 and 2017 using BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen were included. All patients received frontline rituximab-containing chemoimmunotherapy and had chemosensitive disease pre-HCT. Early chemoimmunotherapy failure was defined as not achieving complete remission (CR) after frontline chemoimmunotherapy or relapse within 1 year of initial diagnosis. The primary outcome was overall survival (OS). RESULTS The study cohort was divided into 2 groups: BEAM (n = 667) and R-BEAM (n = 195). On multivariate analysis, no significant difference was seen in OS (P = .83) or progression-free survival (PFS) (P = .61) across the 2 cohorts. No significant association between the use of rituximab and risk of relapse (P = .15) or nonrelapse mortality (P = .12) was observed. Variables independently associated with lower OS included older age at auto-HCT (P < .001), absence of CR at auto-HCT (P < .001) and early chemoimmunotherapy failure (P < .001). Older age (P < .0002) and non-CR pre-HCT (P < .0001) were also associated with inferior PFS. There was no significant difference in early infectious complications between the 2 cohorts. CONCLUSION In this large registry analysis of DLBCL patients undergoing auto-HCT, the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. Older age, absence of CR pre auto-HCT, and early chemoimmunotherapy failure were associated with inferior survival.

Hitta via bibliotek

Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Cancer

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub